| Original language | English |
|---|---|
| Pages (from-to) | 4736-4739 |
| Number of pages | 4 |
| Journal | Blood Advances |
| Volume | 6 |
| Issue number | 16 |
| DOIs | |
| State | Published - Aug 23 2022 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Blood Advances, Vol. 6, No. 16, 23.08.2022, p. 4736-4739.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma
T2 - a subgroup analysis from the LOTIS-2 study
AU - Alderuccio, Juan P.
AU - Ai, Weiyun Z.
AU - Radford, John
AU - Solh, Melhem
AU - Ardeshna, Kirit M.
AU - Lunning, Matthew A.
AU - Hess, Brian T.
AU - Zinzani, Pier L.
AU - Stathis, Anastasios
AU - Carlo-Stella, Carmelo
AU - Hamadani, Mehdi
AU - Kahl, Brad S.
AU - Ungar, David
AU - Kilavuz, Turk
AU - Yu, Eric
AU - Qin, Yajuan
AU - Caimi, Paolo F.
N1 - Funding Information: consultant and has financial relationships with BeiGene, Karyo-pharm, Gilead/Kite Pharma, Daiichi Sankyo, Novartis, Kyowa Kirin, AbbVie, Celgene, Verastem, Janssen, Myeloid Therapeutics, Astra-Zeneca, Acrotech, ADC Therapeutics, Legend, Spectrum, Mor-phoSys, and TG Therapeutics. B.T.H. is on the speakers’ bureaus of Bristol Myers Squibb and AstraZeneca and is an advisory board member of ADC Therapeutics. P.L.Z. is consultant to Verastem, MSD, EUSA Pharma, and Sanofi; is a member of the Board of Directors, speakers’ bureaus, or advisory committees of ADC Therapeutics (advisory board agreement), Verastem, Celltrion, Gilead, Janssen-Cilag, Bristol Myers Squibb, Servier, Sandoz, MSD, Immune Design, Celgene, Portola, Roche, EUSA Pharma, and Kyowa Kirin. A.S. served as consultant to Bayer and Eli Lilly and advisor to Roche and Janssen, received institutional research funding from Roche, AbbVie, Pfizer, Bayer, Merck, Novartis, ADC Therapeutics, and MEI Therapeutics, and received travel grants from AbbVie and Pharma-Mar. C.C.-S. has been a consultant to Sanofi; has received research funding from ADC Therapeutics, Roche, and Sanofi and honoraria from AstraZeneca, Bristol Myers Squibb, Incyte, Janssen Oncology, Takeda, and ADC Therapeutics; is a member of the Board of Directors, speakers’ bureaus, or advisory committees of Sanofi, ADC Therapeutics, Bristol Myers Squibb, Celgene, Karyopharm Therapeutics, and Roche. M.H. has received research funding from Takeda, Spectrum Pharmaceuticals, and Astellas Pharma; has been a consultant to Janssen, Incyte Corporation, ADC Therapeutics, Celgene Corporation, Omeros, Verastem, and MorphoSys; and has been on the speaker’s bureaus of Sanofi Genzyme, AstraZeneca, and Bei-Gene. B.S.K. has been a consultant to AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Celgene, Teva, Janssen, MTEM, Bayer, Incyte, Adaptive, Genentech, Roche, MEI, KITE, TG Therapeutics, Epizyme, and Takeda. D.U., T.K., and Y.Q. are employees of ADC Therapeutics with ownership interests. E.Y. is an employee of ADC Therapeutics and has ownership interests in Zentalis Pharma and Merck. P.F.C. has received research funding from ADC Therapeutics and grants from Genentech; has been a consultant to ADC Therapeutics, Kite Pharmaceuticals, Verastem, Seattle Genetrics, Amgen, and TG Therapeutics and is on the speakers’ bureau of Celgene. Funding Information: Funding for the original study was provided by ADC Therapeutics, SA. J.P.A. is supported by the Peykoff Initiative of the Lymphoma Research Foundation.
PY - 2022/8/23
Y1 - 2022/8/23
UR - https://www.scopus.com/pages/publications/85136494015
U2 - 10.1182/bloodadvances.2022007782
DO - 10.1182/bloodadvances.2022007782
M3 - Letter
C2 - 35790100
AN - SCOPUS:85136494015
SN - 2473-9529
VL - 6
SP - 4736
EP - 4739
JO - Blood Advances
JF - Blood Advances
IS - 16
ER -